+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Reduced incidence of Kaposi's sarcoma and of systemic non-hodgkin's lymphoma in HIV-infected individuals treated with highly active antiretroviral therapy



Reduced incidence of Kaposi's sarcoma and of systemic non-hodgkin's lymphoma in HIV-infected individuals treated with highly active antiretroviral therapy



International Journal of Cancer 103(1): 142-144



Oxygen deficiency in tumors reduces the efficacy of nonsurgical treatment modalities such as conventional radiotherapy and chemotherapy. Since tumor perfusion is directly affected by the vascular resistance to flow of vessels feeding the tumor, vasodilator drugs might be a way to increase tumor blood flow and oxygenation. The effects of nitric oxide (NO) donor administration on tumor oxygenation, perfusion and radiation sensitivity were studied in the FSaII tumor model. Local tumor oxygenation was measured using electron paramagnetic resonance oximetry and a fiberoptic probe, OxyLite. We concomitantly measured the modulation of tumor blood flow by laser Doppler flowmetry. We determined FSaII tumor regrowth delay after isosorbide dinitrate administration and irradiation compared to carbogen breathing before irradiation and with X-rays alone. Administration of the NO donor improved the FSaII tumor pO(2) concomitant with an increase in tumor blood flow. We also demonstrated an increase in FSaII tumor radiation sensitivity after isosorbide dinitrate administration, which was similar to the effect of carbogen breathing in the same tumor model. Administration of isosorbide dinitrate could be considered in terms of improvement in tumor blood flow and a possible concomitant increase in accessibility of chemosensitizing agents to the tumor, particularly in terms of modification of the tumor response to irradiation.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 035625127

Download citation: RISBibTeXText

PMID: 12455069

DOI: 10.1002/ijc.10790


Related references

Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma. International Journal of Cancer 98(6): 916-922, 20 April, 2002

Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. JAIDS Journal of Acquired Immune Deficiency Syndromes 21(Suppl. 1): S34-S41, 1999

Highly active antiretroviral therapy does not protect against Kaposi's sarcoma in HIV-infected individuals. Aids 14(14): 2217-2218, 2000

Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study. Journal of Acquired Immune Deficiency Syndromes 21(Suppl. 1): S34, 1999

Systemic non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 99(11): 4250-4251, 2002

Impact of highly active antiretroviral therapy in the treatment of HIV-infected patients with systemic non-Hodgkin's lymphoma. Acta Oncologica 41(2): 192-196, 2002

Patterns of lymphotropic herpesvirus viraemia in HIV-infected patients with Kaposi's sarcoma treated with highly active antiretroviral therapy and liposomal daunorubicin. Aids 14(14): 2215-2217, 2000

A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Annals of Internal Medicine 143(4): 265-273, 2005

The impact of Kaposi sarcoma and non-Hodgkin lymphoma on mortality of people with AIDS in the highly active antiretroviral therapies era. Cancer Epidemiology 34(3): 257-261, 2010

A prognostic index for systemic AIDS-related non-hodgkin lymphoma treated in the era of highly active antiretroviral therapy (vol 143, pg 265, 2005). Annals of Internal Medicine 144(8): 620, 2006

Virological efficacy in Hiv-infected patients affected by non-hodgkin lymphoma, treated with antiblastic chemotherapy and highly active antiretroviral therapy. Scandinavian Journal of Infectious Diseases 35(s106): 49-53, 2003

Virological efficacy in HIV-infected patients affected by non-Hodgkin lymphoma, treated with antiblastic chemotherapy and highly active antiretroviral therapy. Scandinavian Journal of Infectious Diseases. Supplementum 106: 49-53, 2003

Regression of Kaposi's sarcoma lesions following highly active antiretroviral therapy in an HIV-infected patient. International Journal of Std and Aids 19(11): 786-788, 2008

A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa. Journal of Acquired Immune Deficiency Syndromes 60(2): 150-157, 2012

Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. British Journal of Cancer 99(5): 800-804, 2008